Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC

Revolution Medicines, Inc. (NASDAQ: RVMD) has initiated patient treatment in the RASolute 309 clinical trial, which is a global, randomized Phase 3 study. This trial is assessing the efficacy of the combination of RASONQUE (daraxonrasib) and zoldonrasib as a first-line treatment for adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).